Byrne C, Smart C R, Chu K C, Hartmann W H
Environmental Epidemiology Branch, National Cancer Institute, Bethesda, Maryland 20892.
Cancer. 1994 Jul 1;74(1 Suppl):301-10. doi: 10.1002/cncr.2820741315.
This study considers breast cancer survival patterns by age group among women diagnosed in the Breast Cancer Detection Demonstration Project (BCDDP) to provide insight into the nature of breast cancer and suggest a possible explanation as to why the results of the randomized clinical trials differ for women younger than 50 and those 50 or older. Based on the findings of several randomized clinical trials, there is a general consensus that breast cancer screening provides a significant benefit for women aged 50-69. From these trials, there is little evidence of a short term benefit and uncertainty regarding any long term benefit of mammographic screening for women aged 40-49.
The BCDDP was not a randomized trial, but a nationwide breast cancer screening program conducted between 1973-1980, in which all participants received annual physical and mammographic examinations. Using the BCDDP data, this study calculated 14-year breast cancer survival among 4051 women diagnosed with breast cancer between 1973 and 1980 and followed through 1988 and 1989.
In all, 598 women died of breast cancer, resulting in an overall 14-year breast cancer survival of 83.4% (standard error = 0.007). Breast cancer survival varied by tumor type, lymph node status, tumor size, and stage at diagnosis. For most of the cases, however, both the distribution and breast cancer survival rates were similar for women aged 40-49, 50-59, and 60-69 across all prognostic indicators. Only breast cancer survival among women with invasive breast cancer who had a primary tumor 5 cm or larger or with positive lymph nodes differed by age, with women aged 60-69 at diagnosis having poorer survival. Analyses by modality of detection conducted in a subset of 2739 cases indicated that the 34.6% of the cases detected by mammography alone had the highest overall breast cancer survival rates (90.9%), while the 32.2% of the cases detectable by both physical examination and mammography had the lowest breast cancer survival (79.0%). Overall, women diagnosed with breast cancer in the BCDDP had a survival advantage if diagnosed with either a smaller tumor or no positive lymph nodes, or if their breast cancer was detected by mammography alone. For women with large tumors (> or = 5 cm), the survival was 80.8% for ages 40-49, 72.1% for ages 50-59, and 61.7% for ages 60-69.
Due to the higher breast cancer survival rates among women aged 40-49 with poorer prognostic characteristics, the breast cancer survival advantage for having a smaller tumor, no positive lymph nodes, or breast cancer detected by mammography alone was lower for women aged 40-49 than women aged 50 or older at diagnosis. These differences in survival advantage may help to account for the differences in mortality by age in the randomized clinical trials.
本研究通过乳腺癌检测示范项目(BCDDP)中确诊的女性按年龄组分析乳腺癌生存模式,以深入了解乳腺癌的本质,并为为何50岁以下和50岁及以上女性的随机临床试验结果不同提供一种可能的解释。基于多项随机临床试验的结果,人们普遍认为乳腺癌筛查对50 - 69岁的女性有显著益处。从这些试验中,几乎没有证据表明乳腺钼靶筛查对40 - 49岁女性有短期益处,且对于任何长期益处存在不确定性。
BCDDP并非随机试验,而是一项1973 - 1980年开展的全国性乳腺癌筛查项目,所有参与者均接受年度体格检查和乳腺钼靶检查。利用BCDDP数据,本研究计算了1973年至1980年间确诊乳腺癌并随访至1988年和1989年的4051名女性的14年乳腺癌生存率。
共有598名女性死于乳腺癌,总体14年乳腺癌生存率为83.4%(标准误 = 0.007)。乳腺癌生存率因肿瘤类型、淋巴结状态、肿瘤大小和诊断时的分期而异。然而,在大多数情况下,40 - 49岁、50 - 59岁和60 - 69岁女性在所有预后指标方面的分布和乳腺癌生存率相似。仅原发性肿瘤5厘米或更大或淋巴结阳性的浸润性乳腺癌女性的乳腺癌生存率因年龄而异,诊断时年龄在60 - 69岁的女性生存率较差。对2739例病例子集进行的检测方式分析表明,仅通过乳腺钼靶检测出的病例中34.6%的总体乳腺癌生存率最高(90.9%),而通过体格检查和乳腺钼靶均可检测出的病例中32.2%的乳腺癌生存率最低(79.0%)。总体而言,如果被诊断为肿瘤较小或无淋巴结阳性,或者乳腺癌仅通过乳腺钼靶检测出,BCDDP中被诊断为乳腺癌的女性具有生存优势。对于肿瘤较大(≥5厘米)的女性,40 - 49岁的生存率为80.8%,50 - 59岁为72.1%,60 - 69岁为61.7%。
由于40 - 49岁预后特征较差的女性乳腺癌生存率较高,诊断时40 - 49岁女性因肿瘤较小、无淋巴结阳性或乳腺癌仅通过乳腺钼靶检测出而具有的乳腺癌生存优势低于50岁或以上女性。这些生存优势的差异可能有助于解释随机临床试验中按年龄划分的死亡率差异。